John McKearn
Chairman at Arch Oncology, Inc.
Net worth: 136 280 $ as of 31/03/2024
Profile
John P.
McKearn occupies the position of Chairman for Arch Oncology, Inc. and Managing Director at RiverVest Venture Management LLC.
Dr. McKearn is also on the board of 7 other companies.
In his past career Dr. McKearn was President & Chief Executive Officer for Kalypsys, Inc., Head-Discovery Research at Searle & Co., Inc., Senior Scientist at E.I.
du Pont de Nemours & Co., Head-Discovery Research at Pharmacia Corp., Head-Discovery Research at G.D.
Searle LLC, Research Associate at Washington University in St. Louis and Member of Basel Institute for Immunology.
He received a doctorate from The University of Chicago and an undergraduate degree from Northern Illinois University.John McKearn, PhD, is a Managing Director at RiverVest Venture Partners.
John has almost 30 years’ experience as a successful “drug hunter and developer” in both large and small biopharma, including a decade in small-cap and venture-backed companies.
Prior to joining RiverVest, he was president and CEO of Kalypsys, Inc., and has served on the boards of IDM Pharma, Inc. (acquired by Takeda), Epimmune and Keel Pharmaceuticals, Inc. John worked as a scientist with Searle / Pharmacia, from 1987-2003, including head of discovery research from 1997-2003.
Through his efforts, John helped establish the groundwork for new studies that led to the commercialization of several major products, including DayPro, Arthrotec, and most notably, Celebrex, one of the leading pharmaceuticals to treat arthritis.
Prior to 1987, John was a senior scientist at E.I.
DuPont de Nemours and Company; a member of the Basel Institute for Immunology in Basel, Switzerland; and a research associate in the Department of Microbiology and Immunology at Washington University in St. Louis.
John completed his PhD in immunology from the University of Chicago and his BS in biology from Northern Illinois University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ALLAKOS, INC.
0.12% | 16/01/2024 | 108,159 ( 0.12% ) | 136 280 $ | 31/03/2024 |
John McKearn active positions
| Companies | Position | Start |
|---|---|---|
RiverVest Venture Management LLC
 RiverVest Venture Management LLC Investment ManagersFinance RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Thomas Melzer, Craig Andrew and Jay Schmelter. The firm is headquartered in St. Louis, Missouri. | Private Equity Investor | 01/04/2008 |
Arch Oncology, Inc.
 Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | Chairman | 16/08/2016 |
OncoResponse, Inc.
 OncoResponse, Inc. BiotechnologyHealth Technology OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA. | Director/Board Member | - |
Good Therapeutics, Inc.
 Good Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Good Therapeutics, Inc. operates as a biotechnology company. It develops "context-dependent" protein drugs that sense biomarkers and respond with a therapeutic activity. The company was founded by John Mulligan in 2016 and is headquartered in Seattle, WA. | Director/Board Member | - |
Wugen, Inc.
 Wugen, Inc. Packaged SoftwareTechnology Services Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO. | Director/Board Member | 25/08/2022 |
| OxaluRx, Inc. | Director/Board Member | - |
Bonum Therapeutics, Inc.
 Bonum Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Bonum Therapeutics, Inc. is a privately held American company that focuses on generating a new class of therapeutics based on a proven technology platform. Bonum Therapeutics is based in an undisclosed location and was founded in 2022 by the Good Therapeutics team. The company's technology utilizes principles of allosteric regulation to create highly active and less toxic medicines, which can be applied to a wide range of therapeutic areas, including oncology, autoimmunity, metabolic disorders, and pain management. The company's molecules combine a sensor component directed against a specific biological marker and a therapeutic component. The company is backed by a group of leading venture investors, including Codon Capital, Roche Venture Fund, RiverVest Venture Partners, 3x5 Partners, Digitalis Ventures, and Vivo Capital. The company was founded by John Mulligan, who has been the CEO since incorporation. | Director/Board Member | - |
BioGenerator (Venture Capital)
 BioGenerator (Venture Capital) Investment ManagersFinance BioGenerator (Venture Capital) (BioGenerator) is a venture capital subsidiary of BioGenerator founded in 2003. The firm is headquartered in St. Louis, Missouri. | Private Equity Investor | - |
Former positions of John McKearn
| Companies | Position | End |
|---|---|---|
| ALLAKOS INC. | Director/Board Member | 25/05/2023 |
| ░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░ ░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
| ░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Training of John McKearn
| The University of Chicago | Doctorate Degree |
| Northern Illinois University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ALLAKOS INC. | Health Technology |
| Private companies | 20 |
|---|---|
EIDP, Inc.
 EIDP, Inc. Chemicals: AgriculturalProcess Industries EIDP, Inc. engages in the provision of science-based products and services. It operates through the Seed and Crop Protection segments. The Seed segment develops and supplies advanced germplasm and traits that produce optimum yield for farms around the world. The Crop Protection segment serves the global agricultural input industry with products that protect against weeds, insects and other pests, and disease, and that improve overall crop health both above and below ground via nitrogen management and seed-applied technologies. The company was founded by Eleuthere Irenee du Pont in 1802 and is headquartered in Indianapolis, IN. | Process Industries |
| Epimmune, Inc. | Health Technology |
Kalypsys, Inc.
 Kalypsys, Inc. Pharmaceuticals: MajorHealth Technology Kalypsys, Inc. discovered and developed novel, first-in-class therapeutic agents to address unmet medical needs in respiratory and inflammatory diseases. The firm advanced its proprietary lead program, a novel, non-corticosteroid small molecule formulated for intranasal delivery, into clinical proof of concept studies. The company was founded by Pratik Shah, Jeremy S. Caldwell, Randall W. King, Kevin D. Lustig, Peter G. Schultz and Robert Downs in 2001 and was headquartered in Solana Beach, CA. | Health Technology |
| Keel Pharmaceuticals, Inc. | |
ZS Pharma, Inc.
 ZS Pharma, Inc. Pharmaceuticals: MajorHealth Technology ZS Pharma, Inc. engages in the development of development and commercialization of non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases. It develops treatment of hyperkalemia. It also focuses on clinical development, novel technology, and clinical trials. The company was founded by Alvaro F. Guillem and Donald Jeffrey Keyser on February 5, 2008 and is headquartered in San Mateo, CA. | Health Technology |
Lumena Pharmaceuticals, Inc.
 Lumena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lumena Pharmaceuticals, Inc. developed oral therapeutics for rare liver diseases. The firm was engaged in the development and commercialization of novel products for rare cholestatic liver diseases and serious metabolic disorders, such as nonalcoholic steatohepatitis. The company was founded by Bronislava Gedulin and Michael G. Grey in January 2011 and was headquartered in San Diego, CA. | Health Technology |
Pharmacia Corp.
 Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ. | Health Technology |
RiverVest Venture Management LLC
RiverVest Venture Management LLC Investment ManagersFinance RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Thomas Melzer, Craig Andrew and Jay Schmelter. The firm is headquartered in St. Louis, Missouri. | Finance |
IDM Pharma, Inc.
 IDM Pharma, Inc. Pharmaceuticals: MajorHealth Technology IDM Pharma, Inc. develops products for the destruction of cancer cells. Its products activate the immune system or prevent recurrence by triggering adaptive immune response. The company was founded in established on October 1987 and is headquartered in Cambridge, MA. | Health Technology |
BioGenerator (Venture Capital)
BioGenerator (Venture Capital) Investment ManagersFinance BioGenerator (Venture Capital) (BioGenerator) is a venture capital subsidiary of BioGenerator founded in 2003. The firm is headquartered in St. Louis, Missouri. | Finance |
Adarza BioSystems, Inc.
 Adarza BioSystems, Inc. Electronic Equipment/InstrumentsElectronic Technology Adarza BioSystems, Inc. develops and manufacturers a multiplex immunoassay technology that can identify proteins and genetic markers in medical specimens. The firm operates as a medical diagnostics company which also develops a rapid and label-free biological assay platform for measuring clinical and point-of-care samples and also its technology allows hundreds of tests to be run simultaneously on a single chip. The company was founded by Benjamin L. Miller, Randolph R. Henke, Terry Gronwall and Christopher C. Striemer in 2008 and is headquartered in St. Louis, MO. | Electronic Technology |
Searle & Co., Inc.
 Searle & Co., Inc. Investment ManagersFinance Searle & Co., Inc. provides investment advisory services. The business continuity plan addresses data back up and recovery, all mission critical systems, financial and operational assessments, alternative communications with customers, employees, regulators, alternate physical location of employees, critical supplier, contractor, bank and counter-party impact, regulatory reporting and assuring their customers prompt access to their funds and securities if they are unable to continue their business. The company was founded in 1982 and is headquartered in Greenwich, CT | Finance |
Otonomy, Inc.
 Otonomy, Inc. BiotechnologyHealth Technology Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm’s product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA. | Health Technology |
| G.D. Searle LLC | |
Arch Oncology, Inc.
Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | Commercial Services |
OncoResponse, Inc.
OncoResponse, Inc. BiotechnologyHealth Technology OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA. | Health Technology |
Good Therapeutics, Inc.
Good Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Good Therapeutics, Inc. operates as a biotechnology company. It develops "context-dependent" protein drugs that sense biomarkers and respond with a therapeutic activity. The company was founded by John Mulligan in 2016 and is headquartered in Seattle, WA. | Health Technology |
Wugen, Inc.
Wugen, Inc. Packaged SoftwareTechnology Services Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO. | Technology Services |
| OxaluRx, Inc. | Miscellaneous |
Bonum Therapeutics, Inc.
Bonum Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Bonum Therapeutics, Inc. is a privately held American company that focuses on generating a new class of therapeutics based on a proven technology platform. Bonum Therapeutics is based in an undisclosed location and was founded in 2022 by the Good Therapeutics team. The company's technology utilizes principles of allosteric regulation to create highly active and less toxic medicines, which can be applied to a wide range of therapeutic areas, including oncology, autoimmunity, metabolic disorders, and pain management. The company's molecules combine a sensor component directed against a specific biological marker and a therapeutic component. The company is backed by a group of leading venture investors, including Codon Capital, Roche Venture Fund, RiverVest Venture Partners, 3x5 Partners, Digitalis Ventures, and Vivo Capital. The company was founded by John Mulligan, who has been the CEO since incorporation. | Commercial Services |
- Stock Market
- Insiders
- John McKearn
